Exagen (XGN) Liabilities and Shareholders Equity (2018 - 2026)

Exagen (XGN) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $52.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 28.94% year-over-year to $52.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231.6 million (up 30.17% YoY) and the FY2025 annual result came in at $58.0 million, up 29.84% from the prior year.
• Liabilities and Shareholders Equity fell to $52.0 million in Q1 2026, from $58.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $122.0 million in Q1 2022 to a low of $40.3 million in Q1 2025.
• A 5-year average of $67.0 million and a median of $58.8 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 40.03% — and 2025, when it jumped 44.07%.
• Tracing XGN's Liabilities and Shareholders Equity over 5 years: stood at $86.2 million in 2022, then sank by 33.96% to $56.9 million in 2023, then retreated by 21.52% to $44.7 million in 2024, then increased by 29.84% to $58.0 million in 2025, then retreated by 10.45% to $52.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $52.0 million (Q1 2026), $58.0 million (Q4 2025), and $62.8 million (Q3 2025), per Business Quant data.